Efectividad y seguridad de valganciclovir comparado con ganciclovir, valaciclovir y aciclovir, en pacientes receptores de trasplante de órganos sólidos

Agudelo Berruecos, Yuli; Vanegas Escamilla, Egdda Patricia; Arias Barrera, Carlos Andrés; González, Natalia; García, Paola; Aristizabal, Arbey; Arroyave, Mady; Delgado, María Inés; Eliecer García, Jorge.
Bogotá; IETS; dic. 2014. 57 p. tab, ilus.
Monografía en Español | BRISA, LILACS | ID: biblio-847133

Documentos relacionados

  1. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
  2. Tricyclic Derivative of Acyclovir and Its Esters in Relation to the Esters of Acyclovir Enzymatic Stability: Enzymatic Stability Study.
  3. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients.
  4. Rapid determination of acyclovir, its main metabolite 9-carboxymethoxymethylguanine, ganciclovir, and penciclovir in human serum using LC-MS/MS.
  5. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
  6. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
  7. PharmGKB summary: acyclovir/ganciclovir pathway.
  8. High-Dose Acyclovir for Cytomegalovirus Prophylaxis in Seropositive Abdominal Transplant Recipients.
  9. Development and Validation of an HPLC-UV Method for the Quantification of Acyclovir and Ganciclovir in the Plasma of Pediatric Immunocompromised Patients.
  10. C-5 hydroxyethyl and hydroxypropyl acyclonucleosides as substrates for thymidine kinase of herpes simplex virus type 1 (HSV-1 TK): syntheses and biological evaluation.